{
  "study_id": "NCT00863655",
  "study_title": "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2",
  "table_name": "Table 1",
  "table_title": "Summary of adverse events",
  "description": "Although the user requested baseline demographics, that table was not present in the provided document. This JSON represents the 'Summary of adverse events' table found on page 3.",
  "footnotes": [
    "ÂªDeaths occurring >28 days after end of treatment are not included.",
    "EVE, everolimus; EXE, exemestane; PBO, placebo."
  ],
  "groups": [
    {
      "name": "EVE + EXE",
      "n": 482
    },
    {
      "name": "PBO + EXE",
      "n": 238
    }
  ],
  "characteristics": [
    {
      "original_label": "Serious adverse events",
      "standardized_name": "Serious Adverse Events",
      "category": "Adverse Events",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 157.0,
          "percentage": 32.6,
          "raw_string": "157 (32.6)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 15.5,
          "raw_string": "37 (15.5)"
        }
      ]
    },
    {
      "original_label": "Suspected to be drug-related",
      "standardized_name": "Drug-Related Serious Adverse Events",
      "category": "Adverse Events",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Serious Adverse Events",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 63.0,
          "percentage": 13.1,
          "raw_string": "63 (13.1)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.7,
          "raw_string": "4 (1.7)"
        }
      ]
    },
    {
      "original_label": "Grade 3/4 adverse events",
      "standardized_name": "Grade 3-4 Adverse Events",
      "category": "Adverse Events",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 55.2,
          "raw_string": "266 (55.2)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 70.0,
          "percentage": 29.4,
          "raw_string": "70 (29.4)"
        }
      ]
    },
    {
      "original_label": "Suspected to be drug-related",
      "standardized_name": "Drug-Related Grade 3-4 Adverse Events",
      "category": "Adverse Events",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Grade 3-4 Adverse Events",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 197.0,
          "percentage": 40.9,
          "raw_string": "197 (40.9)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 8.4,
          "raw_string": "20 (8.4)"
        }
      ]
    },
    {
      "original_label": "Adverse events leading to treatment discontinuation",
      "standardized_name": "Adverse Events Leading to Treatment Discontinuation",
      "category": "Adverse Events",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 140.0,
          "percentage": 29.0,
          "raw_string": "140 (29.0)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 5.0,
          "raw_string": "12 (5.0)"
        }
      ]
    },
    {
      "original_label": "On-treatment deaths",
      "standardized_name": "On-Treatment Deaths",
      "category": "Adverse Events",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Total",
      "standardized_name": "Total On-Treatment Deaths",
      "category": "Adverse Events",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "On-Treatment Deaths",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 4.6,
          "raw_string": "22 (4.6)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.7,
          "raw_string": "4 (1.7)"
        }
      ]
    },
    {
      "original_label": "Related to disease progression",
      "standardized_name": "On-Treatment Deaths Related to Disease Progression",
      "category": "Adverse Events",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Total On-Treatment Deaths",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 2.9,
          "raw_string": "14 (2.9)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.3,
          "raw_string": "3 (1.3)"
        }
      ]
    },
    {
      "original_label": "Related to adverse events",
      "standardized_name": "On-Treatment Deaths Related to Adverse Events",
      "category": "Adverse Events",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Total On-Treatment Deaths",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 1.7,
          "raw_string": "8 (1.7)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.4,
          "raw_string": "1 (0.4)"
        }
      ]
    },
    {
      "original_label": "Total treatment exposure, patient-years",
      "standardized_name": "Total Treatment Exposure",
      "unit": "patient-years",
      "category": "Treatment Exposure",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "numeric_single",
          "value": 378.0,
          "raw_string": "378"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "numeric_single",
          "value": 103.0,
          "raw_string": "103"
        }
      ]
    },
    {
      "original_label": "Exposure-adjusted on-treatment deaths (deaths per patient-year)",
      "standardized_name": "Exposure-Adjusted On-Treatment Deaths",
      "unit": "deaths per 100 patient-years",
      "category": "Adverse Events",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "other",
          "value": 5.8,
          "count": 22.0,
          "raw_string": "22 (5.8)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "other",
          "value": 3.9,
          "count": 4.0,
          "raw_string": "4 (3.9)"
        }
      ]
    },
    {
      "original_label": "On-treatment deaths <=4 months from randomization",
      "standardized_name": "On-Treatment Deaths (<=4 months)",
      "category": "Adverse Events",
      "time_point": "<=4 months from randomization",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Total",
      "standardized_name": "Total On-Treatment Deaths (<=4 months)",
      "category": "Adverse Events",
      "time_point": "<=4 months from randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "On-Treatment Deaths (<=4 months)",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 2.3,
          "raw_string": "11 (2.3)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.7,
          "raw_string": "4 (1.7)"
        }
      ]
    },
    {
      "original_label": "Related to disease progression",
      "standardized_name": "On-Treatment Deaths Related to Disease Progression (<=4 months)",
      "category": "Adverse Events",
      "time_point": "<=4 months from randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Total On-Treatment Deaths (<=4 months)",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.2,
          "raw_string": "6 (1.2)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.3,
          "raw_string": "3 (1.3)"
        }
      ]
    },
    {
      "original_label": "Related to adverse events",
      "standardized_name": "On-Treatment Deaths Related to Adverse Events (<=4 months)",
      "category": "Adverse Events",
      "time_point": "<=4 months from randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Total On-Treatment Deaths (<=4 months)",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.1,
          "raw_string": "5 (1.1)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.4,
          "raw_string": "1 (0.4)"
        }
      ]
    },
    {
      "original_label": "On-treatment deaths >4 months after randomization",
      "standardized_name": "On-Treatment Deaths (>4 months)",
      "category": "Adverse Events",
      "time_point": ">4 months after randomization",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Total",
      "standardized_name": "Total On-Treatment Deaths (>4 months)",
      "category": "Adverse Events",
      "time_point": ">4 months after randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "On-Treatment Deaths (>4 months)",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 2.3,
          "raw_string": "11 (2.3)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Related to disease progression",
      "standardized_name": "On-Treatment Deaths Related to Disease Progression (>4 months)",
      "category": "Adverse Events",
      "time_point": ">4 months after randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Total On-Treatment Deaths (>4 months)",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 1.7,
          "raw_string": "8 (1.7)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Related to adverse events",
      "standardized_name": "On-Treatment Deaths Related to Adverse Events (>4 months)",
      "category": "Adverse Events",
      "time_point": ">4 months after randomization",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Total On-Treatment Deaths (>4 months)",
      "group_data": [
        {
          "group_name": "EVE + EXE",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.6,
          "raw_string": "3 (0.6)"
        },
        {
          "group_name": "PBO + EXE",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "raw_string": "0"
        }
      ]
    }
  ]
}